- Home
- KPRX vs MEGL Comparison
KPRX vs MEGL Comparison
Compare KPRX & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- MEGL
- Stock Information
- Founded
- KPRX 1998
- MEGL 2016
- Country
- KPRX United States
- MEGL Hong Kong
- Employees
- KPRX N/A
- MEGL N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MEGL Finance: Consumer Services
- Sector
- KPRX Health Care
- MEGL Finance
- Exchange
- KPRX Nasdaq
- MEGL Nasdaq
- Market Cap
- KPRX 10.0M
- MEGL 9.0M
- IPO Year
- KPRX N/A
- MEGL 2022
- Fundamental
- Price
- KPRX $3.26
- MEGL $0.48
- Analyst Decision
- KPRX Strong Buy
- MEGL
- Analyst Count
- KPRX 1
- MEGL 0
- Target Price
- KPRX $10.00
- MEGL N/A
- AVG Volume (30 Days)
- KPRX 34.9K
- MEGL 89.6K
- Earning Date
- KPRX 11-08-2024
- MEGL 10-30-2024
- Dividend Yield
- KPRX N/A
- MEGL N/A
- EPS Growth
- KPRX N/A
- MEGL N/A
- EPS
- KPRX 1.69
- MEGL N/A
- Revenue
- KPRX $16,020,000.00
- MEGL $1,976,138.00
- Revenue This Year
- KPRX N/A
- MEGL N/A
- Revenue Next Year
- KPRX N/A
- MEGL N/A
- P/E Ratio
- KPRX $2.04
- MEGL N/A
- Revenue Growth
- KPRX N/A
- MEGL 67.75
- 52 Week Low
- KPRX $3.00
- MEGL $0.41
- 52 Week High
- KPRX $8.98
- MEGL $1.47
- Technical
- Relative Strength Index (RSI)
- KPRX 43.44
- MEGL 45.38
- Support Level
- KPRX $3.30
- MEGL $0.49
- Resistance Level
- KPRX $4.04
- MEGL $0.54
- Average True Range (ATR)
- KPRX 0.28
- MEGL 0.03
- MACD
- KPRX -0.01
- MEGL -0.00
- Stochastic Oscillator
- KPRX 7.14
- MEGL 15.99
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.